Phase I Study of Arsenic Trioxide

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York,
New York10021

Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients
who have advanced solid tumors.

Study summary:

OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of arsenic trioxide in adult and
pediatric patients with advanced solid tumors. II. Determine the pattern of clinical adverse
experience of arsenic trioxide in this patient population. III. Evaluate evidence of
clinical responsiveness to this treatment regimen.
OUTLINE: This is a dose escalation, open label study. Patients are stratified by age
(pediatric vs adult). Patients receive arsenic trioxide IV over 1-2 hours once daily for 3
consecutive days then once weekly for 5 weeks. Patients with stable or responding disease
receive additional courses of therapy every 8 weeks for up to 1 year in the absence of
disease progression or unacceptable toxicity. Patients receive escalating doses of arsenic
trioxide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the
dose preceding that at which 2 or more patients out of 6 experience dose limiting toxicity.
Patients are followed for at least 1 month after treatment.
PROJECTED ACCRUAL: Approximately 48 patients will be accrued for this study.

Criteria:

DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumor Relapsed from or
resistant to at least 1 course of standard anticancer therapy AND/OR Lack of standard
therapy that is known to be beneficial in the underlying disease
PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-3 Life expectancy:
Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
Hepatic: Bilirubin no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine
no greater than 2.5 times ULN Other: Not pregnant or nursing Negative pregnancy test
Fertile patients must use effective contraception during and for at least 4 months
following study No active serious infections that are not controlled by antibiotics
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
Disease Characteristics No other concurrent chemotherapy Endocrine therapy: See Disease
Characteristics Radiotherapy: See Disease Characteristics No concurrent radiotherapy
Surgery: See Disease Characteristics Other: No other concurrent investigational agents

NCT ID:

NCT00003630

Primary Contact:

Study ChairSteven Soignet, MDMemorial Sloan-Kettering Cancer Center

Backup Contact:

N/A

Location Contact:

New York, New York 10021United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: September 26, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.